Author response: Robust estimation of cancer and immune cell-type proportions from bulk tumor ATAC-Seq data Article Swipe
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.7554/elife.94833.2.sa0
· OA: W4401392429
Assay for Transposase-Accessible Chromatin sequencing (ATAC-Seq) is a widely used technique to explore gene regulatory mechanisms. For most ATAC-Seq data from healthy and diseased tissues such as tumors, chromatin accessibility measurement represents a mixed signal from multiple cell types. In this work, we derive reliable chromatin accessibility marker peaks and reference profiles for most non-malignant cell types frequently observed in the tumor micro-environment. We then integrate these data into the EPIC deconvolution framework () to quantify cell-type heterogeneity in bulk ATAC-Seq data. Our EPIC-ATAC tool accurately predicts non-malignant and malignant cell fractions in tumor samples. When applied to a breast cancer cohort, EPIC-ATAC accurately infers the immune contexture of the main breast cancer subtypes.
